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Dr Dirk E. M. Van Raemdonck (Leuven, Belgium). I would
like to thank Dr Osaki and colleagues for a clear presentation
reporting an in-depth analysis of the late outcomes in a cohort of
18 lung transplant recipients from so-called Maastricht Category
III controlled non–heart-beating donors. The LTx group at the Uni-
versity of Wisconsin is to be congratulated with this largest and
longest single-center series on LTx from DCD donors reported
thus far. The experience of the group dates back to 1993, when
Bob Love got interested and started the use of lungs from this
type of donor in whom other organs, like the kidney, liver, and pan-
creas, were already recovered for transplantation at Madison.
The authors conclude that the long-term patient and graft sur-
vival in lung transplant recipients from donors after cardiac death
are equivalent to those from donors after brain death and that these
donors therefore could be safely used to expand the donor pool.
Nevertheless, the reported doubled incidence of bronchial compli-
cations in these recipients might be a concern that should be further
investigated.
I have 3 questions for the presenter that I will pose one at a time.
The authors define the WIT as the period between the with-
drawal of life support, extubation, and the start of cold perfusion,
on average about 30 minutes. In my opinion this definition is not
entirely correct because in some donors spontaneous breathing
continues after extubation and the blood pressure remains sufficient
to perfuse the organs for a longer period of time, and therefore the
lungs cannot be considered as being ischemic already. To compare
results between different institutions across the world and to enter
data in an international register, such as the one from the ISHLT, we
should agree on the same definition of warm ischemia: either from
cardiac arrest until cold flush perfusion or when the blood pressure
in the donor decreases to less than 50 mm Hg. Therefore my ques-
tion is this: Can the authors comment on this definition and also
provide us with the exact time between cardiac arrest or electrome-
chanical dissociation and the start of cold perfusion?
Dr Osaki. Thank you very much, Professor Van Raemdonck, for
your kind comments and the question about the appropriate defini-
tion of WIT. Dr Snell and colleagues, the group from Australia, sug-
gested in a recent publication that the definition of WIT should be
considered as the interval between starting at a systolic blood pres-
sure of less than 50 mm Hg and the initiation of cold flush preserva-
tion of the organs for controlled DCD donors. We agree with this
definition. In our organ procurement organization, since 2006, the
changes in hemodynamics from extubation to cardiac arrest are
recorded. However, 15 of 18 cases DCD donor LTx were performed
before that time, and the data were not documented. Thus we were
not able to obtain records of the hemodynamic changes during the
time between extubation and declaration of death on most DCD
donors. In terms of the exact time between cardiac arrest and cold
flush of preservation solution, the mean time was 9 minutes.
Dr Van Raemdonck. All donors were extubated in the operat-
ing room, and some donors were returned to the ward if cardiac
arrest did not occur within 2 hours after withdrawal of support.
Can the authors tell us what percentage of organs could not be re-
covered from these potential donors and whether they believe that
any sedative drugs could be given to improve the donor’s comfort
and relieve the family from further awaiting the inevitable death in
the hours thereafter?1314 The Journal of Thoracic and Cardiovascular SurDr Osaki. During the study period, from January 1993 to April
2009, 269 DCD donor procurements were performed in our local
organ procurement organization. From those, 18 DCD donor lungs
were used, indicating a lung recovery rate of 6.7%. Although we
tried, we could not identify the number of potential DCD donors
in which cardiac arrest did not occur and were returned to the inten-
sive care unit or hospital ward. In addition, the total number of
DCD donor offers made to our program was not available from
our database. In terms of care of DCD donor candidates, I cannot
make any comments about the use of sedative drugs or end-of-
life management for those DCD donor candidates; however, I am
sure those were applied by the physicians managing the donor
candidates.
Dr Van Raemdonck. Finally, the freedom from airway compli-
cations was significantly lower in recipients of organs from DCD
donors. This raises the question of whether the additional warm
ischemic interval contributes to the damage of the larger airways
subjected to impaired healing. The use of an additional retrograde
pulmonary flush delivered through the 4 pulmonary veins is be-
lieved to preserve the bronchial tree better through collateral perfu-
sion of the bronchial arteries. Did your group at Wisconsin
implement such a retrograde flush in your DCD donors, and if
so, was this equally compared between both groups?
Dr Osaki. We appreciate your suggestion on a possible method
to prevent airway complications in the DCD donor lung grafts. The
possibility of increased airway complications deserves further in-
vestigation. About the specific question regarding the use of retro-
grade flush to the pulmonary veins, I can say that this has been part
of our routine technique of lung graft recovery. In an animal study
with a pig model, Binns and colleagues suggested that central
airways might be more susceptible to the lack of perfusion during
ischemia than lung parenchymal cells, which can maintain some
aerobic metabolism through ventilation. Certainly the effects of
warm ischemia on bronchial healing deserve further investigation.
Dr Van Raemdonck. Once again, I congratulate you on a nice
presentation. Thank you.
Dr Love. Dirk, I can help with some of those question because in
point of fact, none of the authors were involved primarily with any
of these cases except for the case of bronchial dehiscence. That
bronchial dehiscence, which I repaired myself, was a technical
problem and not ischemia as reported here. None of the other bron-
chial problems in the initial 17 patients were a major problem for
the patient and were managed bronchoscopically without signifi-
cant morbidity.
The development of DCD donor LTx as a clinical reality during
my tenure at the University of Wisconsin was adopted over many
years. It has been gratifying to see the adoption of the techniques
of donor management and selection, recipient selection, and valida-
tion of my results at many centers in Europe, North America, and
Australia. Retrograde flush at procurement was used in all patients,
and over the years, there was about 30% occurrence of nonretrieval
of lungs when going out for procurement.
Dr Bryan F. Meyers (St Louis, Mo). I think this is something
that is a great idea in principle, but when it gets down to the spe-
cifics, it becomes more challenging to evaluate. When Dr Love
started doing this, I am sure he was extremely selective about the
DCD donors that he accepted and the interaction between the
DCD donor and the risk of the recipient the lung was going into.gery c May 2010
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the quality of the donor lung and then look at potential recipients for
one that is suitable. I also consider the distance and the likely length
of ischemic time. There are a lot of factors that we have already put
into the decision making that would help make this work out, and
presenting this without knowing the bias behind all those careful
selections would perhaps make this look equivalent when it is really
not as equivalent as it might seem. I agree with more data collection
to learn more about the decision making and the other unrecorded
factors, but these are great results, and they make DCD donors ap-
pear equivalent, but I think that there were a lot of accommodations
that were made to make DCD donors work out as well as possible in
the beginning.
Dr John H. Dark (Newcastle, United Kingdom). I would like to
echo what others have said about the role of Bob Love in both
originating this field and driving this particular series of patients
forward.
My question is about the PGD incidence and the use of nitric
oxide. You have clearly put a huge amount of work into collecting
these data over the years. Your PGD incidence would perhaps seem
a little higher than that been recorded in European and Australian
series, although the numbers are all small. Was there any correla-
tion between any of the preoperative variables in terms of WIT
or cold ischemic time and PGD?
Dr Osaki. Thank you very much for your question.
Actually we did analyze the correlation between the WIT or cold
ischemic time and the incidence of airway complications; however,
there was no correlation between these parameters.
Dr De Oliveira. With regard to Dr Meyers’ comments, before
we start the indiscriminate use of DCD donor lungs, I think we
have to be very careful because the definition of WIT is not yet
very clear. It goes from a few minutes in countries in which eutha-
nasia is allowed to as long as 90 minutes, as in one of the patients in
our series. There is no question that there is a selection bias as well.
Most DCD donor lungs meet standard criteria. I do not think there is
that much experience about the use of extended criteria or marginal
DCD donor lungs.
Having said that, I think this is an extremely important technique.
In many situations I believe DCD donor lungs have been used as
a salvage procedure, and I do not think those patients would have
received a lung transplant on time if they had to wait for a BDD.
Finally, I think there is a lot of potential in the future to combine
the use of the ex vivo lung perfusion system and the use of DCD
donor organs. DCD donor organs could potentially be evaluated
before LTx.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). If I can follow
up on that, we have done about 11 or 12 DCD organ transplanta-
tions and because we have the ex vivo trial going, we have made
it a policy to do ex vivo assessment of all of the DCD donor lungs
in our program before implanting them to learn a little bit more
about the process. DCD donor lungs in many cases could in fact
be better organs and not exposed to the ravages of inflammatory in-
jury of brain death and brain stem coning and so on, but on the otherThe Journal of Thoracic and Carhand, if death or cessation of circulation occurs slowly, you can go
through an agonal phase of low blood pressure and shock with the
possibility of developing a shock lung. Therefore it might well be
a less predictable organ source. I do think that the ability to be
able to assess the lung before you implant it might help us to define
which organs are going to be usable.
Dr Bartosz Kubisa (Szczecin, Poland). Thank you for your nice
presentation.
The good results that you have received with these donors, are
they far away from those of the non–heart-beating donors? Can
we also have the same good results in the future from the non–
heart-beating donors? What is the time difference in the case of
your donors and the patients when the heart actually stopped and
the explantation of lungs is after an hour or 2 or a longer period
of time?
To clarify, I understand you are referring to category I and II
donors in whom cardiac activity has already stopped? I guess the
question is this: Do you expect to get equivalently good results
with Maastricht category I and II donors as you have achieved
with the category III donors?
Dr Osaki. I do not think so.
Dr Keshavjee. I think that that is another area of interest; obvi-
ously Steen has looked at it, and Dirk Van Raemdonck and others
have explored this area as well. Andres Varela in Madrid has
performed transplantations in a number of patients. There is no
doubt that the category I and II donor lungs have a much more sig-
nificant PGD and a lower 1-year survival than what has been pub-
lished worldwide with BDDs. Once again, those are lungs that have
taken a bigger hit, and I think again that there might be some good
organs in that group, but there is more variability, and that speaks
again for the advantage of the ability to be able to test or recondition
the lungs before you implant them.
Dr Waleed Saleh (Riyadh, Saudi Arabia). You mentioned that
the airway complications after DCD donor LTX were higher?
Dr Osaki. Yes.
Dr Saleh. What were they specifically, more dehiscence or
stenosis or infection?
Dr Osaki. Actually, we had 5 airway complications. One had
ischemic bronchial dehiscence on POD 8, but the other 4 patients
had bronchial stenosis, and 2 of them had an Aspergillus species
infection.
Dr Stephen D. Cassivi (Rochester, Minn). I have a quick com-
ment. I think Bob Love and his group are to be congratulated once
more. This is especially true in this day and age of tremendous trans-
parency in transplantation in North America and when in the United
States every outcome is on the Internet within 6 months. In transplan-
tation our outcomes are scrutinized very, very closely. This has a real
potential to stifle innovation such as this. Therefore for Dr Love to
move forward with something like this is a testament to his ability
to take on risk and manage it successfully. Congratulations.
Dr Osaki. Thank you very much.
Dr Keshavjee. I think that is exactly what Tom Spray was allud-
ing to in his Presidential Address. Congratulations again, Bob.diovascular Surgery c Volume 139, Number 5 1315
